Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Use of bispecifics and CAR T cells in South America

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Choosing 1st line TKI Wisely in patients with CML